Abstract
Objective: This study was designed to determine whether biological markers related to apoptosis or proliferative activity are associated with the clinical outcome in patients with squamous cell carcinoma (SCC) of the larynx treated with concurrent chemoradiotherapy. Methods: Immunostaining with antibodies specific to p53, bcl-2, bax, and MIB-1 was performed to evaluate expression of these proteins in formalin-fixed, paraffin-embedded specimens of 59 patients treated with concurrent chemoradiotherapy (carboplatin, 100 mg/m 2, four to six times every week; total radiation dose of 40–65 Gy over 4–6.5 weeks). Results: Multivariate analysis indicated that nodal status was a significant indicator of overall survival (OS; P=0.001). Patients with bcl-2 positive tumors had better OS than those with bcl-2 negative tumors in both univariate ( P=0.002) and multivariate analyses ( P<0.001). In the univariate analysis, a considerable difference in OS was observed among the expressions of bax ( P=0.077), MIB-1 proteins ( P=0.071), and OS, but the difference was not statistically significant. Conclusion: This study indicates that nodal status is the major prognostic factor in patients with SCC of the larynx treated with concurrent chemoradiotherapy. These results provide useful information for predicting prognosis. Further analysis of biological factors is needed to evaluate the value as predictive markers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
